Coronavirus Vaccine in the U.S. Superforecasters see a 53% probability that 25 million doses of an FDA-approved COVID-19 vaccine will be available by March 2021 vs. 69% two weeks ago. Image: Goldman Sachs Global Investment Research
Coronavirus Vaccine and Jet Fuel Demand Goldman Sachs expects jet fuel demand to recover next year, with the availability of a coronavirus vaccine by the second-quarter of 2021. Image: Goldman Sachs Global Investment Research
Coronavirus Vaccine in the U.S. A vaccine for Covid-19 will accelerate the path to economic normalization. Image: Goldman Sachs Global Investment Research
COVID-19 Lockdown Portfolio vs. COVID-19 Reopening Portfolio (Coronavirus) Since January 2020, the COVID-19 “lockdown portfolio” has outperformed the COVID-19 “reopening portfolio.” Image: BofA Global Investment Strategy
Coronavirus Vaccine in the United States Will a coronavirus vaccine be approved by the FDA between October 2020 and March 2021? Image: Goldman Sachs Global Investment Research
Coronavirus Crisis and U.S. Corporate Bankruptcies The coronavirus crisis triggers a record number of U.S. corporate bankruptcies, despite record levels of federal aid. Image: Financial Times
Coronavirus – Daily Deaths from COVID-19 in the U.S. and Currently Hospitalized due to COVID-19 Both of these graphs show encouraging signs in the United States, as the growth in new COVID-19 cases continues to decline. Image: BofA Global Research
U.S. Real GDP Relative to Pre-Coronavirus Level Goldman Sachs is optimistic and has raised its 2021 estimate of U.S. real GDP growth to 6.2%. Image: Goldman Sachs Global Investment Research
Coronavirus – Daily Number of New COVID-19 Cases in the U.S. The United States surpasses 4 million officially reported coronavirus cases, while COVID-19 cases keep climbing. Image: The Daily Shot – The Wall Street Journal
Coronavirus – U.S. Infections Outlook U.S. infections are expected to peak by mid-August. Image: Gavekal, Macrobond